Eurofins Scientific reports adjusted net profit of €568 million for the past year, or €2.71 per share, and adjusted EBITDA down 9.9% to €1.36 billion, at the upper end of its target range of €1.32-1.37 billion.

At 6.51 billion euros, the bio-analysis services provider's sales fell by 2.9% due to a drop in revenues from Covid-19 tests and reagents, while those of its core business grew by 7.1% in organic terms.

A dividend of 0.50 euros per share for 2023 will be proposed at the AGM scheduled for April 25, up 74% on 2018 (the last before the Covid-19 pandemic), representing an average annual growth rate of 11.7%.

Eurofins is targeting adjusted EBITDA of between 1.525 and 1.575 billion euros, as well as sales of between 7.075 and 7.175 billion, for 2024. It also confirms its 2027 targets of an adjusted EBITDA margin of 24% and sales approaching 10 billion.

Copyright (c) 2024 CercleFinance.com. All rights reserved.